Is the cost-effectiveness threshold cost-effective in cancer therapy?
Journal Title: JOURNAL OF HEALTH POLICY & OUTCOMES RESEARCH - Year 2015, Vol 8, Issue 2
Abstract
Introduction: To compare availability of innovative cancer drugs in countries with established cost-effectiveness threshold (Great Britain, Czech Republic, Sweden and Poland) and where this criterion is not used (Germany, France, Italy), and to assess the relationship between the reimbursement system and the expenditures and health outcomes. Methods: The analysis of reimbursement decisions concerning innovative cancer drugs approved by the European Medicines Agency in the years 2012-2013 and the available data concerning incidence, 5-year relative survival rate and the treatment costs of breast, lung, colon and prostate cancer. Results: The assessment included 19 innovative drugs. Most of them were covered by reimbursement in countries without a cost-effectiveness threshold — 80.7%, compared to the countries with a cost-effectiveness threshold — 59.6% (48.7% including Poland). Three products were financed in all reimbursement systems, with the exception of Poland: Perjeta, Xalkori and Xtandi. In countries without the cost-effectiveness threshold the health outcomes expressed as 5-year relative survival were better compared to EU in general or to most of countries which use the cost-effectiveness threshold, whereas expenditures per capita in most cancers were diversified — large (15-27 €, Germany) or similar to the countries with the cost-effectiveness threshold (6-13 €, France and Italy). In Poland for most evaluated cancers the lowest 5-year relative survival was noted, with the lowest expenditure per capita (5-9 €) simultaneously. Conclusions: The percentage of reimbursed innovative cancer drugs is higher in countries without the cost-effectiveness threshold, where better health outcomes are observed. Limited access to innovative therapies resulting from restrictive financial criteria may have a significant impact on health outcomes in cancer treatment.
Authors and Affiliations
Łukasz Kaczyński, Beata Serafin, Patrycja Prząda-Machno, Marcin Kaczor
Keywords
Related Articles
- EP ID EP192167
- DOI 10.7365/JHPOR.2015.2.6
- Views 108
- Downloads 0
Assessment of Quality of life (QoL) in postmenopausal osteoporosis in the Lublin region
Introduction: Postmenopausal osteoporosis is related to the changes in female body during menopause. The aim was to assess the quality of life of women in the Lublin region suffering from postmenopausal osteoporosis. Me...
Treatment and prevention of bleeding in adult hemophilia A patients with inhibitor – economic analysis.
Hemophilia A is caused by an absence or deficiency of coagulation factor VIII. Patients with hemophilia may experience recurrent spontaneous hemarthroses or internal bleeding. Following the treatment with factor VIII con...
Association between EQ-5D-3L population norms and gross domestic product based on purchasing power parity in European countries
Background One of the of health-related quality of life (HRQoL) measurement methods is the EQ-5D questionnaire. Population norms of the EQ-5D can be used to compare profiles for patients with specific conditions with da...
The disposal of unused and/or out of date medications in the community pharmacy setting in Poland – a challenge for pharmaceutical public health and pharmaceutical care
It has been proven that even small concentrations of certain drugs in the environment can be toxic to plants, but also fatal for animals and humans. The only proper way to prevent this phenomenon is to minimize the adver...
The assessment of the impact of thrombocytopenia symptoms on the patients’ daily activities with the use of TSIDAV vignette
Objective: Assessment of the impact of thrombocytopenia symptoms on patients’ daily activities using vignettes. Methods: Vignettes were used to collect information from adult patients and children’s caregivers in order...